Bendopnea and risk of adverse clinical outcomes in ambulatory patients with systolic heart failure

American Heart Journal

Volumn 183, Issue , 2017, Pages 102-107

  Thibodeau, Jennifer T ^a   Jenny, Benjamin E ^a   Maduka, Jeomi O ^a   Divanji, Punag H ^a   Ayers, Colby R ^a   Araj, Faris ^a   Amin, Alpesh A ^a   Morlend, Robert M ^a   Mammen, Pradeep P A ^a   Drazner, Mark H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; METOLAZONE; NITROGEN; SODIUM; TORASEMIDE; UREA;

ADULT; ADVERSE OUTCOME; ARTICLE; BENDOPNEA; BODY MASS; CARDIOVASCULAR MORTALITY; CLINICAL OUTCOME; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG MEGADOSE; DYSPNEA; FEMALE; FOLLOW UP; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HOSPITAL ADMISSION; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; NEW YORK HEART ASSOCIATION CLASS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE PRESSURE; RISK ASSESSMENT; RISK FACTOR; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE; UREA NITROGEN BLOOD LEVEL; AGED; BODY POSITION; COMPLICATION; HOSPITALIZATION; KAPLAN MEIER METHOD; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK; STATISTICS AND NUMERICAL DATA;

AGED; DYSPNEA; FEMALE; HEART FAILURE, SYSTOLIC; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; POSTURE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK;

EID: 85006961177     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2016.09.011     Document Type: Article

References (37)

1. 1. Thibodeau, J.T., Turer, A.T., Gualano, S.K., et al. Characterization of a novel symptom of advanced heart failure: bendopnea. JACC Heart Fail 2:1 (2014), 24–31.
2. 2. Dominguez-Rodriguez, A., Thibodeau, J.T., Abreu-Gonzalez, P., et al. Association between bendopnea and key parameters of cardiopulmonary exercise testing in patients with advanced heart failure. J Card Fail 22:2 (2016), 163–165.
3. 3. Nohria, A., Tsang, S.W., Fang, J.C., et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41:10 (2003), 1797–1804.
4. 4. Drazner, M.H., Rame, J.E., Stevenson, L.W., et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 345:8 (2001), 574–581.
5. 5. Damman, K., Voors, A.A., Hillege, H.L., et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail 12:9 (2010), 974–982.
6. 6. Aaronson, K.D., Schwartz, J.S., Chen, T.M., et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95:12 (1997), 2660–2667.
7. 7. Morley, D., Brozena, S.C., Assessing risk by hemodynamic profile in patients awaiting cardiac transplantation. Am J Cardiol 73:5 (1994), 379–383.
8. 8. Campana, C., Gavazzi, A., Berzuini, C., et al. Predictors of prognosis in patients awaiting heart transplantation. J Heart Lung Transplant 12:5 (1993), 756–765.
9. 9. Lucas, C., Johnson, W., Hamilton, M.A., et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 140:6 (2000), 840–847.
10. 10. Stevenson, L.W., Tillisch, J.H., Hamilton, M., et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 66:19 (1990), 1348–1354.
11. 11. Keogh, A.M., Baron, D.W., Hickie, J.B., Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol 65:13 (1990), 903–908.
12. 12. Azevedo, E.R., Newton, G.E., Floras, J.S., et al. Reducing cardiac filling pressure lowers norepinephrine spillover in patients with chronic heart failure. Circulation 101:17 (2000), 2053–2059.
13. 13. Kaye, D.M., Lambert, G.W., Lefkovits, J., et al. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 23:3 (1994), 570–578.
14. 14. Leri, A., Claudio, P.P., Li, Q., et al. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 101:7 (1998), 1326–1342.
15. 15. Mancini, D.M., Eisen, H., Kussmaul, W., et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 83:3 (1991), 778–786.
16. 16. O'Neill, J.O., Young, J.B., Pothier, C.E., et al. Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers. Circulation 111:18 (2005), 2313–2318.
17. 17. Arena, R., Myers, J., Aslam, S.S., et al. Peak VO2 and VE/VCO2 slope in patients with heart failure: a prognostic comparison. Am Heart J 147:2 (2004), 354–360.
18. 18. Kleber, F.X., Vietzke, G., Wernecke, K.D., et al. Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation 101:24 (2000), 2803–2809.
19. 19. Anand, I.S., Fisher, L.D., Chiang, Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107:9 (2003), 1278–1283.
20. 20. Cleland, J.G., McMurray, J.J., Kjekshus, J., et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 54:20 (2009), 1850–1859.
21. 21. Fonarow, G.C., Peacock, W.F., Phillips, C.O., et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 49:19 (2007), 1943–1950.
22. 22. Januzzi, J.L. Jr., Sakhuja, R., O'Donoghue, M., et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 166:3 (2006), 315–320.
23. 23. Masson, S., Latini, R., Anand, I.S., et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52:12 (2008), 997–1003.
24. 24. Lu, D.Y., Cheng, H.M., Cheng, Y.L., et al. Hyponatremia and worsening sodium levels are associated with long-term outcome in patients hospitalized for acute heart failure. J Am Heart Assoc, 4(3), 2016, e002668.
25. 25. Hillege, H.L., Nitsch, D., Pfeffer, M.A., et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113:5 (2006), 671–678.
26. 26. Fonarow, G.C., Adams, K.F. Jr., Abraham, W.T., et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293:5 (2005), 572–580.
27. 27. Blair, J.E., Pang, P.S., Schrier, R.W., et al. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J 32:20 (2011), 2563–2572.
28. 28. Klein, L., Massie, B.M., Leimberger, J.D., et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail 1:1 (2008), 25–33.
29. 29. Weinfeld, M.S., Chertow, G.M., Stevenson, L.W., Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 138:2 Pt 1 (1999), 285–290.
30. 30. Nohria, A., Hasselblad, V., Stebbins, A., et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 51:13 (2008), 1268–1274.
31. 31. Clark, A.L., Chyu, J., Horwich, T.B., The obesity paradox in men versus women with systolic heart failure. Am J Cardiol 110:1 (2012), 77–82.
32. 32. Clark, A.L., Fonarow, G.C., Horwich, T.B., Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis 56:4 (2014), 409–414.
33. 33. Lavie, C.J., Alpert, M.A., Arena, R., et al. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail 1:2 (2013), 93–102.
34. 34. Lavie, C.J., Cahalin, L.P., Chase, P., et al. Impact of cardiorespiratory fitness on the obesity paradox in patients with heart failure. Mayo Clin Proc 88:3 (2013), 251–258.
35. 35. Shah, R., Gayat, E., Januzzi, J.L. Jr., et al. Body mass index and mortality in acutely decompensated heart failure across the world: a global obesity paradox. J Am Coll Cardiol 63:8 (2014), 778–785.
36. 36. Sharma, A., Lavie, C.J., Borer, J.S., et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol 115:10 (2015), 1428–1434.
37. 37. Lavie, C.J., Osman, A.F., Milani, R.V., et al. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol 91:7 (2003), 891–894.